Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CACNA1G | O43497 | 10/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 10/20 | 0.37 |
| ▸ | CACNA1I | Q9P0X4 | 10/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10908636 | 0.80 | ALDH1A1 (0.43) | NOTUMALDH1A1CACNA1GCACNA1HCACNA1I | |
| SCHEMBL13632458 | 0.79 | DRD2 (0.49) | CACNA1GCACNA1HCACNA1IBRD4SIRT1 | |
| SCHEMBL21938738 | 0.77 | NOTUM (0.41) | NOTUMALDH1A1CASP1CASP7LTA4H | |
| SCHEMBL31378007 | 0.76 | NOTUM (0.51) | NOTUMALDH1A1CACNA1GCASP1CASP7 | |
| SCHEMBL30099061 | 0.76 | NOTUM (0.47) | NOTUMALDH1A1CASP1CASP7 | |
| SCHEMBL11984354 | 0.73 | CACNA1G (0.43) | NOTUMCACNA1GCACNA1HCACNA1ICASP1 | |
| SCHEMBL3750926 | 0.72 | NOTUM (0.44) | NOTUMALDH1A1CASP1CASP7 | |
| SCHEMBL31322157 | 0.71 | L3MBTL1 (0.44) | ALDH1A1LTA4H | |
| SCHEMBL14819922 | 0.70 | SIRT1 (0.54) | CACNA1GCACNA1HCACNA1IBRD4SIRT1 | |
| SCHEMBL10899742 | 0.70 | NOTUM (0.45) | NOTUMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612424-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | REGOR PHARMACEUTICALS, INC. | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612424-B2 | HPK1 inhibitors and uses thereof | NEK11, NEK1, CSNK1A1 | NOTUM 4645/4885ALDH1A1 3619/4885CACNA1G 4269/4885 |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | HIPK1, SIK1, PGK1 | NOTUM 2494/4885ALDH1A1 3740/4885CACNA1G 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.